Novartis vets get $35M to pluck one of the pharma giant’s abandoned drugs off the shelf and put it back into a clinical trial
Back in 2006, Novartis execs scooped up rights to Kyorin’s immunosuppressant drug program for KRP-203, an S1P drug that the pharma giant initially thought had some real potential.
But Mayzent (siponimod) ultimately stole the S1P show at Novartis, which would go on to win a first-in-class FDA OK in multiple sclerosis, with KRP-203 abandoned along the way still in early-stage development.
Until today.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.